Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor offering ...

RFK Jr's attack on the self-affirmed GRAS pathway could shake up the fermentation protein sector, as the FDA prioritises ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

March 18, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems, a medical technology company specializing in novel aesthetic solutions, today announces that it has received approval from Health Canada and ...

Joseph Mossel is the CEO of Ibex Medical Analytics. His career in the tech industry spans more than 20 years, starting off in ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Furthermore, a supplemental New Drug Application ... has demonstrated robust efficacy in clinical studies, enhancing the effectiveness of immunotherapy for NPC. The approval for first-line ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25Progression of preclinical next-generation ...